135 related articles for article (PubMed ID: 3998771)
1. Three-year observation of mesulergine (CU 32-085) in advanced and newly treated parkinsonism.
Schneider E; Baas H; Fischer PA; Japp G
J Neurol; 1985; 232(1):24-8. PubMed ID: 3998771
[TBL] [Abstract][Full Text] [Related]
2. Mesulergine (CU 32-085) in the treatment of Parkinson's disease.
Rascol A; Montastruc JL; Rascol O; Senard JM
Clin Neuropharmacol; 1986; 9(2):146-52. PubMed ID: 3708600
[TBL] [Abstract][Full Text] [Related]
3. Mesulergine and bromocriptine in long-term treatment of advanced parkinsonism.
Baas H; Schneider E; Fischer PA; Japp G
J Neural Transm; 1985; 64(1):45-54. PubMed ID: 4067602
[TBL] [Abstract][Full Text] [Related]
4. Treatment of Parkinson's disease with 8-alpha-amino-ergoline, CU 32-085.
Schneider E; Hubener K; Fischer PA
Neurology; 1983 Apr; 33(4):468-72. PubMed ID: 6682193
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of pergolide and mesulergine.
Lieberman AN; Gopinathan G; Neophytides A
Eur Neurol; 1986; 25(2):86-90. PubMed ID: 3948891
[TBL] [Abstract][Full Text] [Related]
6. Placebo-controlled study of mesulergine in Parkinson's disease.
Jankovic J; Orman J; Jansson B
Neurology; 1985 Feb; 35(2):161-5. PubMed ID: 3881692
[TBL] [Abstract][Full Text] [Related]
7. The long-acting dopamine receptor agonist cabergoline in early Parkinson's disease: final results of a 5-year, double-blind, levodopa-controlled study.
Bracco F; Battaglia A; Chouza C; Dupont E; Gershanik O; Marti Masso JF; Montastruc JL;
CNS Drugs; 2004; 18(11):733-46. PubMed ID: 15330687
[TBL] [Abstract][Full Text] [Related]
8. Studies with bromocriptine. Part 2. Double-blind comparison with levodopa in idiopathic parkinsonism.
Kartzinel R; Shoulson I; Calne DB
Neurology; 1976 Jun; 26(6 PT 1):511-3. PubMed ID: 778655
[TBL] [Abstract][Full Text] [Related]
9. Mesulergine in early Parkinson's disease: a double blind controlled trial.
Dupont E; Mikkelsen B; Jakobsen J
J Neurol Neurosurg Psychiatry; 1986 Apr; 49(4):390-5. PubMed ID: 3517235
[TBL] [Abstract][Full Text] [Related]
10. Clinical experience with cabergoline in patients with advanced Parkinson's disease treated with levodopa.
Marsden CD
Drugs; 1998; 55 Suppl 1():17-22. PubMed ID: 9483166
[TBL] [Abstract][Full Text] [Related]
11. Chronic agonist therapy for Parkinson's disease: a 5-year study of bromocriptine and pergolide.
Goetz CG; Tanner CM; Glantz RH; Klawans HL
Neurology; 1985 May; 35(5):749-51. PubMed ID: 3990974
[TBL] [Abstract][Full Text] [Related]
12. Adjuvant treatment of Parkinson's disease with dopamine agonists: open trial with bromocriptine and CU 32-085.
Jellinger K
J Neurol; 1982; 227(2):75-88. PubMed ID: 6180142
[TBL] [Abstract][Full Text] [Related]
13. Mesulergine (CU32-085) in the treatment of Parkinson's disease.
Pfeiffer RF; Wilken K; Glaeske C
Ann Neurol; 1985 Apr; 17(4):334-6. PubMed ID: 3890700
[TBL] [Abstract][Full Text] [Related]
14. Long-term experience with bromocriptine in advanced parkinsonism. Results after one year's treatment.
Schneider E; Fischer PA
J Neurol; 1982; 228(4):249-58. PubMed ID: 6188812
[TBL] [Abstract][Full Text] [Related]
15. D-1 and D-2 agonists in Parkinson's disease.
Lieberman AN; Goldstein M; Gopinathan G; Neophytides A
Can J Neurol Sci; 1987 Aug; 14(3 Suppl):466-73. PubMed ID: 2960431
[TBL] [Abstract][Full Text] [Related]
16. Bromocriptine versus levodopa in early Parkinson's disease.
Ramaker C; van Hilten JJ
Cochrane Database Syst Rev; 2000; (3):CD002258. PubMed ID: 10908538
[TBL] [Abstract][Full Text] [Related]
17. Parkinson's disease: a comparison of mesulergine and bromocriptine.
Burton K; Larsen TA; Robinson RG; Bratty PJ; Martin WR; Schulzer M; Calne DB
Neurology; 1985 Aug; 35(8):1205-8. PubMed ID: 3895033
[TBL] [Abstract][Full Text] [Related]
18. Treatment of parkinson's disease with bromocriptine.
Lieberman A; Kupersmith M; Estey E; Goldstein M
N Engl J Med; 1976 Dec; 295(25):1400-4. PubMed ID: 989885
[TBL] [Abstract][Full Text] [Related]
19. Bromocriptine in Parkinsonism: long-term treatment, dose response, and comparison with levodopa.
Parkes JD; Debono AG; Marsden CD
J Neurol Neurosurg Psychiatry; 1976 Nov; 39(11):1101-8. PubMed ID: 1036999
[TBL] [Abstract][Full Text] [Related]
20. Early treatment of Parkinson's disease with cabergoline delays the onset of motor complications. Results of a double-blind levodopa controlled trial. The PKDS009 Study Group.
Rinne UK; Bracco F; Chouza C; Dupont E; Gershanik O; Marti Masso JF; Montastruc JL; Marsden CD
Drugs; 1998; 55 Suppl 1():23-30. PubMed ID: 9483167
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
